Uğur Şahin’s most consequential oncology asset began not in Mainz, but in China. Pumitamig, the PD-L1 and VEGF-A bispecific antibody also known as BNT327 or BMS986545, came into BioNTech through its acquisition of Zhuhai-based Biotheus. BioNTech completed that purchase in February 2025 for US$800 million upfront and up to US$150 million in potential payments. Four months later, Bristol Myers Squibb agreed to pay as much as US$11.1 billion across upfront, non-contingent and milestone payments for a global 50-50 development and commercial alliance.
That rapid increase in strategic value is striking, but deal value is not product value. In 2026, pumitamig is entering the expensive part of development. BioNTech and Bristol Myers Squibb expect to have eight global Phase III trials under way by year-end across lung and other solid tumours. Encouraging Phase II signals now need to survive larger, more diverse populations and direct comparison with established standards of care.
Şahin ranks fourth because pumitamig captures several forces reshaping Asian and global biotechnology: Chinese discovery, Western balance sheets, cross-border clinical development and fierce competition around immunotherapy. His leadership test is to ensure that BioNTech converts the asset’s deal momentum into evidence, while controlling research cost and preserving strategic choices across a broad oncology portfolio.
From an US$800 million acquisition to an US$11.1 billion headline
BioNTech’s purchase of Biotheus gave it full global rights to pumitamig and a research and manufacturing base in Zhuhai. The transaction was a calculated way to consolidate an asset that BioNTech had already licensed for development outside Greater China. By acquiring the company, it removed split ownership and gained a Chinese team with experience in bispecific antibodies.
The Bristol Myers Squibb agreement then changed the economics. BioNTech received US$1.5 billion upfront. It is due a further US$2 billion in non-contingent anniversary payments through 2028 and may receive up to US$7.6 billion tied to development, regulatory and commercial milestones. The partners share global development cost and profit equally, subject to the detailed terms of their agreement.
The structure gives BioNTech substantial non-dilutive capital and access to Bristol Myers Squibb’s oncology-development and commercial infrastructure. It also halves the product economics and requires joint decision-making. For a programme running multiple pivotal trials, shared cost reduces exposure. For an asset that ultimately succeeds, shared profit limits the upside BioNTech could have retained alone.
The US$11.1 billion figure should therefore be handled carefully. US$3.5 billion is upfront or non-contingent across several years; the remaining US$7.6 billion depends on milestones. Not all milestones have the same probability or timing, and headline value does not disclose the full cost of achieving them. The better measure is the net cash BioNTech receives while trials progress, followed by risk-adjusted profit from approved indications.
The mechanism must produce a clinical advantage
Pumitamig is designed to block PD-L1, an immune checkpoint used by tumours to suppress attack, while neutralising VEGF-A, which supports tumour blood vessels and contributes to an immunosuppressive microenvironment. Combining the two actions in one molecule could concentrate activity and improve the interaction between immune response and tumour vasculature.
The scientific logic is credible, but the category is not empty. Checkpoint inhibitors are entrenched across many cancers, often in combinations. Other developers, including companies originating in China, are advancing bispecifics that pair immune-checkpoint and VEGF pathways. Each new entrant must show not only response, but a useful balance of survival, tolerability, dosing and cost.
BioNTech and Bristol Myers Squibb reported encouraging interim results from the global Phase II ROSETTA Lung-02 study in previously untreated advanced non-small-cell lung cancer in May 2026. BioNTech has also presented promising Chinese data in extensive-stage small-cell lung cancer. Those findings support further development, but cross-trial comparisons can mislead. Patient characteristics, control regimens and follow-up differ.
Phase III design is where the competitive claim becomes measurable. Choice of comparator, patient stratification, geography and combination partner will determine whether the studies answer commercially relevant questions. A statistically positive result may still be difficult to adopt if the incremental benefit is modest, toxicity complicates treatment or the regimen costs materially more than an established alternative.
Eight Phase III trials create portfolio risk inside one asset
Running eight pivotal studies can create enormous option value. Positive results in several tumour types could establish pumitamig as a platform medicine with broad revenue. Parallel development also compresses time by learning across studies and building regulatory familiarity. The price is a concentrated operational commitment before the earliest pivotal answers are known.
Clinical sites compete for patients and staff. Diagnostic requirements differ by tumour. Drug supply must support several protocols and combination regimens. Safety signals need to be assessed consistently across a growing database. Even with Bristol Myers Squibb sharing cost and capability, BioNTech must maintain programme governance that can stop, redesign or reprioritise studies when evidence changes.
The risk is correlation. If the mechanism underperforms for a fundamental reason, several trials may disappoint together. Portfolio breadth across indications does not provide the same diversification as independent mechanisms. Investors should examine whether each trial tests a distinct biological and commercial hypothesis or simply extends the same assumption to another market.
Success also creates complexity. Multiple approvals would require coordinated manufacturing, launches and evidence generation across countries. Capacity built for an antibody must meet demand while maintaining quality and cost. A global franchise developed jointly by two large organisations needs clear responsibility for market access, medical affairs and regional execution.
BioNTech can afford the trials, but affordability is not return
BioNTech finished 2025 with about €17.2 billion in cash, cash equivalents and security investments. Full-year revenue was €2.87 billion, while research and development expense reached €2.10 billion and the net loss was €1.14 billion. The group entered 2026 with exceptional financial resources for a biotechnology company, largely built during the Covid-19 vaccine period.
First-quarter 2026 revenue fell to €118.1 million from €182.8 million a year earlier, and the net loss widened to €531.9 million. Cash and security investments remained about €16.8 billion. BioNTech guided to 2026 revenue of €2.0 billion to €2.3 billion, adjusted research and development expense of €2.2 billion to €2.5 billion and selling, general and administrative expense of €700 million to €800 million.
The Bristol Myers Squibb payments soften the cash burden, but the cost base remains substantial. BioNTech is funding several oncology modalities, infectious-disease work and manufacturing capability in addition to pumitamig. The key financial question is not whether it can pay for development. It is whether each euro spent improves the probability or speed of an economically meaningful approval.
Şahin has long presented BioNTech as a technology company able to combine mRNA, antibodies, cell therapies and data-driven discovery. Pumitamig now requires a different discipline: concentrating resources around the assets with the clearest evidence. A broad platform narrative cannot protect the income statement if late-stage studies proliferate without priorities.
The China-to-global model is the strategic asset
Pumitamig’s path offers a repeatable model for global drug development. Chinese biotechnology can generate differentiated assets and rapid early clinical evidence. A well-capitalised international company can acquire or license those assets, add global trials and build regulatory reach. A large pharmaceutical partner can then contribute scale for pivotal development and commercialisation.
BioNTech’s Zhuhai research and manufacturing hub gives it more than a contractual connection to that ecosystem. Local scientific teams can identify programmes, support development and maintain relationships in a market that has become central to oncology innovation. The asset is organisational knowledge: knowing which Chinese findings are globally transferable and how to secure rights before competition raises prices.
Cross-border execution has constraints. Chinese and international regulators may require different evidence. Clinical populations and standards of care vary. Data transfer, intellectual property and biologics manufacturing face changing national rules. BioNTech must keep local speed without creating a development package that is hard to use elsewhere.
The model also changes bargaining power. As Chinese developers gain global recognition, they can demand larger upfront payments, retain regional rights or choose among multiple partners. BioNTech’s advantage will depend on whether the Biotheus integration creates a proprietary pipeline rather than making the company another bidder for external assets.
Competition will set the commercial threshold
By the time pumitamig reaches major markets, oncology treatment may have shifted again. Existing checkpoint combinations will have more survival data. Competing bispecifics may be approved or may define new biomarkers. Lower-cost products could influence reimbursement, especially in Asia. A clinically active medicine can still struggle if it arrives without a clear place in treatment.
Pricing will require a coherent argument. A bispecific may simplify the supply and administration of two biological actions, but payers will compare total regimen cost against separate agents and other combinations. If pumitamig is used with chemotherapy or additional medicines, the economic burden rises. Demonstrating fewer hospitalisations, manageable toxicity or longer durable benefit will support access more than mechanism alone.
Manufacturing yield and reliability will also shape gross margin. Bispecific antibodies can be more complex to produce and characterise than conventional antibodies. BioNTech’s and Bristol Myers Squibb’s technical teams need an industrial process ready before pivotal success, without committing excessive capacity too early.
What Şahin must deliver in 2026
The immediate goal is disciplined execution across the expanding pivotal programme. Trial enrolment, protocol consistency and timely safety review matter more than the number of studies announced. Management should explain how it ranks indications, what evidence would change spending and how BMS governance speeds rather than delays decisions.
The next requirement is financial clarity. BioNTech should separate partner payments, programme cost and acquisition-related investment so that shareholders can assess the return on pumitamig independently of the wider pipeline. It should also show how the Zhuhai operation contributes to additional assets, not only the lead programme.
Şahin transformed a Chinese biotechnology acquisition into one of the industry’s largest recent oncology alliances. That was a sophisticated act of scientific selection and dealmaking. The more difficult act is now under way: proving that a promising bispecific can outperform relevant standards across large global trials while earning a return on a sprawling programme. Pumitamig will test whether BioNTech’s post-vaccine reinvention is an operating business or an expensive collection of scientific options.
